查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1592908

流感治疗药物市场：按药物类别、给药方式、流感类型、分销管道、最终用户 - 2025-2030 年全球预测

Influenza Medication Market by Drug Class (Baloxavir, Oseltamivir, Peramivir), Delivery Form (Inhalers, Intravenous, Liquid/Syrup), Influenza Type, Distribution Channel, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年流感治疗市值为34.4亿美元，预计到2024年将达到36亿美元，复合年增长率为5.00%，预计到2030年将达到48.4亿美元。

流感治疗市场由用于预防、缓解和治疗流感症状的物质定义，包括抗病毒药物和各种支持性治疗。这些药物的需求源自于流感的季节性流行和潜在的严重性，这构成了重大的公共卫生挑战。应用范围从个人预防措施到医疗保健组织采用的更广泛的公共卫生策略。最终用途包括医院、药局和网路药局，满足处方药和非处方药的需求。影响市场成长的主要因素包括全球流感预防意识的提高、药物配方的进步以及政府扩大健康措施。还有机会扩展到目前进入受限的新兴市场，并开发更有效的输送机制，例如吸入器和速效製剂。然而，来自学名药的竞争、严格的监管条件以及对疫苗的不愿意等限制和挑战可能会限制市场成长。疫苗技术的持续创新，特别是通用流感疫苗和个人化医疗方法的开发，为成长提供了一个有希望的途径。此外，数位技术的整合，例如人工智慧驱动的流感预测模型，可以增强分销策略和市场渗透效率。这些创新有可能提供以消费者为中心的解决方案，以满足不断变化的健康需求。此外，经济压力会影响消费者的购买力，凸显出具有成本效益的替代方案和取得策略的重要性。儘管市场竞争激烈且由大型製药公司主导，但对于能够提供新颖、高效解决方案的新进业者来说也有空间。根据特定人群的需求客製化您的产品并透过教育宣传活动扩大知名度可以为您带来竞争优势。对于寻求发展的公司来说，专注于与医疗保健提供者的合作并利用人工智慧进行市场洞察和预测将为在这个动态的市场环境中导航和繁荣带来巨大的好处。

主要市场统计
基准年[2023] 34.4亿美元
预测年份 [2024] 36亿美元
预测年份 [2030] 48.4亿美元
复合年增长率（%） 5.00%

市场动态：揭示快速发展的流感药物市场的关键市场洞察

供需的动态交互作用正在改变流感药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 流感疫情在全球不断扩大
    • 政府针对流感管理的措施和宣传计划
    • 对个人化医疗的兴趣日益浓厚
  • 市场限制因素
    • 开发新型流感治疗药物的成本上升
  • 市场机会
    • 流感治疗药物的监管核准迅速增加
    • 开发新配方和输送方法的有利投资
  • 市场挑战
    • 流感药物对健康的不良影响

波特五力：驾驭流感药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解流感药物市场的外部影响

外部宏观环境因素在塑造流感治疗药物市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解流感治疗药物市场的竞争状况

对流感治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

流感治疗市场中的 FPNV 定位矩阵供应商绩效评估

FPNV定位矩阵是评估流感治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了流感治疗药物市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对流感治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地流感流行率上升
      • 政府关于流感管理的措施和宣传计划
      • 个人化医疗方法的成长趋势
    • 抑制因素
      • 开发新型流感治疗药物的成本高昂
    • 机会
      • 流感治疗药物的监管核准激增
      • 开发新配方和管理方法的有利投资
    • 任务
      • 流感药物对健康的不良影响
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依药物类别分類的流感治疗药物市场

  • 巴洛沙韦
  • 奥司他韦
  • 帕拉米韦
  • 扎那米韦

第七章依给药方式分類的流感治疗药物市场

  • 吸入器
  • 静脉
  • 液体/糖浆
  • 锭剂/胶囊

第八章按流感类型分類的流感治疗药物市场

  • A型
  • B型
  • C型
  • D型

第九章流感治疗药物市场：按分销管道

  • 离线
  • 在线的

第 10 章 流感治疗药物市场：依最终使用者分类

  • 门诊手术中心
  • 居家照护设施
  • 医院/诊所

第十一章 美洲流感药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太流感药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲流感药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • AstraZeneca PLC
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • Cocrystal Pharma, Inc.
  • CSL Limited
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Lupin Limited
  • Merck & Co., Inc.
  • NATCO Pharma Limited
  • Novartis AG
  • Pfizer Inc.
  • Qiagen NV
  • Sandoz International GmbH
  • Sanofi SA
  • Shionogi & Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Pharmaceuticals, Inc.
Product Code: MRR-F6513A06BE18

The Influenza Medication Market was valued at USD 3.44 billion in 2023, expected to reach USD 3.60 billion in 2024, and is projected to grow at a CAGR of 5.00%, to USD 4.84 billion by 2030.

The influenza medication market is defined by the substances used to prevent, reduce, or treat flu symptoms, which can include antiviral drugs and various supportive treatments. The necessity of these medications arises from the seasonal prevalence and potential severity of influenza outbreaks, which pose significant public health challenges. The application spans from individual preventive measures to broader public health strategies employed by healthcare institutions. End-use scope includes hospitals, pharmacies, and online drug stores, catering to both prescription and over-the-counter needs. Key factors influencing market growth include increasing global awareness of flu prevention, advancements in drug formulations, and growing governmental health initiatives. Opportunities arise from the potential to expand into emerging markets where access is currently limited, as well as developing more efficient delivery mechanisms like inhalers or faster-acting formulations. However, limitations and challenges such as high competition from generic drugs, stringent regulatory landscapes, and vaccine hesitancy can restrict market growth. Continuous innovation in vaccine technology, particularly in the development of universal influenza vaccines and personalized medicine approaches, offers promising avenues for growth. Additionally, digital technology integration, such as AI-driven flu prediction models, can enhance distribution strategies and market penetration efficiency. These innovations could offer consumer-centric solutions that meet the evolving health needs. Furthermore, economic pressures can affect consumer purchasing power, highlighting the importance of cost-effective alternatives and access strategies. The market is competitive, with large pharmaceutical companies dominating, but there's room for new entrants that can offer novel, efficient solutions. Tailoring products to demographic-specific needs and expanding awareness through education campaigns could provide competitive advantages. For businesses seeking growth, focusing on collaborations with healthcare providers and leveraging AI for market insight and prediction can offer significant benefits in navigating and thriving within this dynamic market landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 3.44 billion
Estimated Year [2024] USD 3.60 billion
Forecast Year [2030] USD 4.84 billion
CAGR (%) 5.00%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Influenza Medication Market

The Influenza Medication Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of influenza across the globe
    • Government initiatives and awareness programs for influenza management
    • Growing inclination towards personalized medicine approaches
  • Market Restraints
    • Associated high cost of novel influenza drug development
  • Market Opportunities
    • Surge in influenza drug approvals from regulatory authorities
    • Favorable investments for development of new formulations and delivery methods
  • Market Challenges
    • Adverse health outcomes of influenza medications

Porter's Five Forces: A Strategic Tool for Navigating the Influenza Medication Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Influenza Medication Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Influenza Medication Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Influenza Medication Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Influenza Medication Market

A detailed market share analysis in the Influenza Medication Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Influenza Medication Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Influenza Medication Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Influenza Medication Market

A strategic analysis of the Influenza Medication Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Influenza Medication Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., AstraZeneca PLC, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Cocrystal Pharma, Inc., CSL Limited, Daiichi Sankyo Company, Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Lupin Limited, Merck & Co., Inc., NATCO Pharma Limited, Novartis AG, Pfizer Inc., Qiagen N.V., Sandoz International GmbH, Sanofi SA, Shionogi & Co., Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Influenza Medication Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Baloxavir, Oseltamivir, Peramivir, and Zanamivir.
  • Based on Delivery Form, market is studied across Inhalers, Intravenous, Liquid/Syrup, and Tablets/Capsules.
  • Based on Influenza Type, market is studied across Type A, Type B, Type C, and Type D.
  • Based on Distribution Channel, market is studied across Offline and Online.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Homecare Facilities, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of influenza across the globe
      • 5.1.1.2. Government initiatives and awareness programs for influenza management
      • 5.1.1.3. Growing inclination towards personalized medicine approaches
    • 5.1.2. Restraints
      • 5.1.2.1. Associated high cost of novel influenza drug development
    • 5.1.3. Opportunities
      • 5.1.3.1. Surge in influenza drug approvals from regulatory authorities
      • 5.1.3.2. Favorable investments for development of new formulations and delivery methods
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse health outcomes of influenza medications
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Influenza Medication Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Baloxavir
  • 6.3. Oseltamivir
  • 6.4. Peramivir
  • 6.5. Zanamivir

7. Influenza Medication Market, by Delivery Form

  • 7.1. Introduction
  • 7.2. Inhalers
  • 7.3. Intravenous
  • 7.4. Liquid/Syrup
  • 7.5. Tablets/Capsules

8. Influenza Medication Market, by Influenza Type

  • 8.1. Introduction
  • 8.2. Type A
  • 8.3. Type B
  • 8.4. Type C
  • 8.5. Type D

9. Influenza Medication Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Offline
  • 9.3. Online

10. Influenza Medication Market, by End-User

  • 10.1. Introduction
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Homecare Facilities
  • 10.4. Hospitals & Clinics

11. Americas Influenza Medication Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Influenza Medication Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Influenza Medication Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies, Inc.
  • 3. AstraZeneca PLC
  • 4. Bio-Rad Laboratories, Inc.
  • 5. Bristol-Myers Squibb Company
  • 6. Cocrystal Pharma, Inc.
  • 7. CSL Limited
  • 8. Daiichi Sankyo Company, Limited
  • 9. Eli Lilly and Company
  • 10. F. Hoffmann-La Roche AG
  • 11. GlaxoSmithKline PLC
  • 12. Lupin Limited
  • 13. Merck & Co., Inc.
  • 14. NATCO Pharma Limited
  • 15. Novartis AG
  • 16. Pfizer Inc.
  • 17. Qiagen N.V.
  • 18. Sandoz International GmbH
  • 19. Sanofi SA
  • 20. Shionogi & Co., Ltd.
  • 21. Sun Pharmaceutical Industries Ltd.
  • 22. Takeda Pharmaceutical Company Limited
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. Viatris Inc.
  • 25. Zydus Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. INFLUENZA MEDICATION MARKET RESEARCH PROCESS
  • FIGURE 2. INFLUENZA MEDICATION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INFLUENZA MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. INFLUENZA MEDICATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. INFLUENZA MEDICATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INFLUENZA MEDICATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INFLUENZA MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INFLUENZA MEDICATION MARKET DYNAMICS
  • TABLE 7. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY LIQUID/SYRUP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLETS/CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TYPE A, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TYPE B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TYPE C, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TYPE D, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOMECARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 238. INFLUENZA MEDICATION MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 239. INFLUENZA MEDICATION MARKET, FPNV POSITIONING MATRIX, 2023